GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Short-Term Debt

Chordia Therapeutics (TSE:190A) Short-Term Debt : 円0.00 Mil (As of Feb. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Short-Term Debt?

Chordia Therapeutics's Short-Term Debt for the quarter that ended in Feb. 2025 was 円0.00 Mil.


Chordia Therapeutics Short-Term Debt Historical Data

The historical data trend for Chordia Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Short-Term Debt Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Short-Term Debt
- - - -

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25
Short-Term Debt Get a 7-Day Free Trial - - - - -

Chordia Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Chordia Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines